JP2004537553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537553A5 JP2004537553A5 JP2003513598A JP2003513598A JP2004537553A5 JP 2004537553 A5 JP2004537553 A5 JP 2004537553A5 JP 2003513598 A JP2003513598 A JP 2003513598A JP 2003513598 A JP2003513598 A JP 2003513598A JP 2004537553 A5 JP2004537553 A5 JP 2004537553A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hmg
- receptor antagonist
- reductase inhibitor
- aldosterone receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 21
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 21
- 229940123934 Reductase inhibitor Drugs 0.000 claims 21
- 229940044551 receptor antagonist Drugs 0.000 claims 21
- 239000002464 receptor antagonist Substances 0.000 claims 21
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 9
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 9
- 229960005370 atorvastatin Drugs 0.000 claims 9
- 229960001208 eplerenone Drugs 0.000 claims 8
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical group C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 7
- 229960000672 rosuvastatin Drugs 0.000 claims 6
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 6
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 150000007513 acids Chemical class 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 229960002965 pravastatin Drugs 0.000 claims 5
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229960002855 simvastatin Drugs 0.000 claims 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 5
- 229960002797 pitavastatin Drugs 0.000 claims 4
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 4
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 3
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 3
- 229960005110 cerivastatin Drugs 0.000 claims 3
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 3
- 229960003765 fluvastatin Drugs 0.000 claims 3
- 229960004844 lovastatin Drugs 0.000 claims 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 3
- 229950009116 mevastatin Drugs 0.000 claims 3
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical group C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 3
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 3
- 229960002256 spironolactone Drugs 0.000 claims 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000008085 renal dysfunction Effects 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30633601P | 2001-07-19 | 2001-07-19 | |
| PCT/US2002/022896 WO2003007993A1 (en) | 2001-07-19 | 2002-07-18 | Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004537553A JP2004537553A (ja) | 2004-12-16 |
| JP2004537553A5 true JP2004537553A5 (enExample) | 2006-01-05 |
Family
ID=23184836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003513598A Pending JP2004537553A (ja) | 2001-07-19 | 2002-07-18 | アルドステロン受容体アンタゴニストおよびＨＭＧＣｏ−Ａレダクターゼ阻害剤の組合せ薬剤 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20030149010A1 (enExample) |
| EP (1) | EP1406660B1 (enExample) |
| JP (1) | JP2004537553A (enExample) |
| KR (1) | KR20040023660A (enExample) |
| CN (1) | CN1537019A (enExample) |
| AP (1) | AP2004002951A0 (enExample) |
| AT (1) | ATE363917T1 (enExample) |
| BR (1) | BR0211274A (enExample) |
| CA (1) | CA2452678A1 (enExample) |
| CO (1) | CO5550464A2 (enExample) |
| DE (1) | DE60220522T2 (enExample) |
| EA (1) | EA200400029A1 (enExample) |
| EC (1) | ECSP044950A (enExample) |
| ES (1) | ES2286270T3 (enExample) |
| GE (1) | GEP20063811B (enExample) |
| IL (1) | IL159588A0 (enExample) |
| IS (1) | IS7093A (enExample) |
| MA (1) | MA27050A1 (enExample) |
| MX (1) | MXPA04000586A (enExample) |
| NO (1) | NO20040211L (enExample) |
| OA (1) | OA12983A (enExample) |
| PL (1) | PL367417A1 (enExample) |
| TN (1) | TNSN04001A1 (enExample) |
| UA (1) | UA76475C2 (enExample) |
| WO (1) | WO2003007993A1 (enExample) |
| ZA (1) | ZA200400288B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901812A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
| PT1773768T (pt) | 2004-07-30 | 2018-11-30 | Exelixis Inc | Derivados de pirrol como agentes farmacêuticos |
| WO2007005941A2 (en) | 2005-07-05 | 2007-01-11 | President And Fellows Of Harvard College | Liver targeted conjugates |
| CN1310941C (zh) * | 2005-07-13 | 2007-04-18 | 南京大学 | 依普利酮的合成方法 |
| BRPI0618379A2 (pt) * | 2005-11-08 | 2011-08-30 | Ranbaxy Lab Ltd | processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico |
| GB0600967D0 (en) * | 2006-01-18 | 2006-03-01 | Imp Innovations Ltd | Methods |
| WO2007106862A2 (en) * | 2006-03-14 | 2007-09-20 | Kinemed, Inc. | The use of statins to stimulate neurogenesis |
| EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| FR2917975B1 (fr) * | 2007-06-26 | 2009-10-16 | Ceva Sante Animale Sa | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains |
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| EP2367554A4 (en) * | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid reflux inhibitor for the treatment of obesity and diabetes |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
| MX337603B (es) * | 2009-11-30 | 2016-03-10 | Adare Pharmaceuticals Inc | Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion. |
| EP4137137A1 (en) | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
| US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
| RS53227B (sr) | 2011-03-01 | 2014-08-29 | Pharnext | Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata |
| DE102011015142A1 (de) * | 2011-03-17 | 2012-09-20 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Agens zur Prophylaxe und Behandlung altersassoziierter Krankheiten und Störungen sowie zur Verlängerung der Lebensdauer |
| US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
| EA038594B1 (ru) | 2011-10-28 | 2021-09-21 | Шайр Хьюман Дженетик Терапис, Инк. | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени |
| JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| KR20160002773A (ko) | 2013-03-15 | 2016-01-08 | 루메나 파마수티컬즈, 인코포레이티드 | 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제 |
| AU2014229050A1 (en) | 2013-03-15 | 2015-10-22 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease |
| US20150199491A1 (en) * | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
| EP4424363B1 (en) | 2019-02-12 | 2026-04-29 | Mirum Pharmaceuticals, Inc. | Methods for increasing growth in pediatric subjects having cholestatic liver disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9609872A (pt) * | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
| KR20010006443A (ko) * | 1997-04-18 | 2001-01-26 | 쥐.디. 씨얼리 앤드 컴퍼니 | 심장혈관 질환 예방에의 시클로 옥시게나제-2 억제제 사용방법 |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| US6638937B2 (en) * | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| WO2000062775A1 (en) * | 1999-04-19 | 2000-10-26 | The Regents Of The University Of Michigan | Compositions and methods for increasing the bioavailability of lactone ring containing drugs |
-
2002
- 2002-07-18 OA OA1200400005A patent/OA12983A/en unknown
- 2002-07-18 UA UA2004010388A patent/UA76475C2/uk unknown
- 2002-07-18 CN CNA028145577A patent/CN1537019A/zh active Pending
- 2002-07-18 CA CA002452678A patent/CA2452678A1/en not_active Abandoned
- 2002-07-18 AT AT02756521T patent/ATE363917T1/de not_active IP Right Cessation
- 2002-07-18 US US10/198,475 patent/US20030149010A1/en not_active Abandoned
- 2002-07-18 DE DE60220522T patent/DE60220522T2/de not_active Expired - Fee Related
- 2002-07-18 MX MXPA04000586A patent/MXPA04000586A/es active IP Right Grant
- 2002-07-18 PL PL02367417A patent/PL367417A1/xx not_active Application Discontinuation
- 2002-07-18 GE GE5410A patent/GEP20063811B/en unknown
- 2002-07-18 ES ES02756521T patent/ES2286270T3/es not_active Expired - Lifetime
- 2002-07-18 EA EA200400029A patent/EA200400029A1/ru unknown
- 2002-07-18 WO PCT/US2002/022896 patent/WO2003007993A1/en not_active Ceased
- 2002-07-18 BR BR0211274-4A patent/BR0211274A/pt not_active IP Right Cessation
- 2002-07-18 JP JP2003513598A patent/JP2004537553A/ja active Pending
- 2002-07-18 AP APAP/P/2004/002951A patent/AP2004002951A0/en unknown
- 2002-07-18 IL IL15958802A patent/IL159588A0/xx unknown
- 2002-07-18 EP EP02756521A patent/EP1406660B1/en not_active Expired - Lifetime
- 2002-07-18 KR KR10-2004-7000846A patent/KR20040023660A/ko not_active Ceased
-
2003
- 2003-12-23 IS IS7093A patent/IS7093A/is unknown
-
2004
- 2004-01-06 TN TNP2004000001A patent/TNSN04001A1/fr unknown
- 2004-01-14 ZA ZA2004/00288A patent/ZA200400288B/en unknown
- 2004-01-15 MA MA27479A patent/MA27050A1/fr unknown
- 2004-01-16 NO NO20040211A patent/NO20040211L/no not_active Application Discontinuation
- 2004-01-19 CO CO04002848A patent/CO5550464A2/es not_active Application Discontinuation
- 2004-01-19 EC EC2004004950A patent/ECSP044950A/es unknown
-
2005
- 2005-08-18 US US11/206,499 patent/US20060003975A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moghadasian | Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors | |
| ES2286270T3 (es) | Combinacion de un antagonista del receptor de aldosterona y un inhibidor de la hmg coa reductasa. | |
| WO2008045170A3 (en) | Statin and omega-3 fatty acids for reduction of apo-b levels | |
| RU2012116079A (ru) | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения | |
| JP2008291034A (ja) | コレステロール吸収阻害剤、ＨＭＧ−ＣｏＡレダクターゼ阻害剤および安定化剤を含有する組成物 | |
| JP2010501550A (ja) | ジヒドロピリジンカルシウムチャネル遮断薬およびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む制御放出性組合せ医薬製剤 | |
| TW201200166A (en) | Pharmaceutical formulation in the form of bilayered tablets comprising HMG-CoA reductase inhibitor and irbesartan | |
| JP2008050367A5 (enExample) | ||
| CA2456732A1 (en) | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor | |
| EP2214653B1 (en) | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use | |
| JP2002525321A5 (ja) | カテーテルによる血管再生を予防または遅らせる医薬組成物の製造のためのコレステロール低下剤の使用 | |
| RU2011124739A (ru) | Композиции, содержащие ингибиторы системы ренин-ангиотензин альдостерона и соединения липоевой кислоты, и их применение для лечения заболеваний, связанных с системой ренин-ангиотензин альдостерона | |
| US20110275649A1 (en) | Combination therapy for the prevention of statin induced diabetes | |
| CN102652746A (zh) | 一种含有氯吡格雷及其药学上可接受的盐的药物组合物及其制备方法 | |
| JP2008513379A5 (enExample) | ||
| HRP20141149T1 (hr) | Dugotrajno lijeäśenje simptomatske sräśane insuficijencije | |
| JP2010526152A5 (enExample) | ||
| JP2005525391A5 (enExample) | ||
| US20020048599A1 (en) | Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation | |
| US20100022556A1 (en) | Therapeutic combinations comprising a long acting dihydropyridine calcium-channel blocker and a statin | |
| Åsberg et al. | Fluvastatin and fluvastatin extended release: a clinical and safety profile | |
| JP2006176498A5 (enExample) | ||
| RU2007148908A (ru) | Составы для снижения риска возникновения вызванной лекарственными средствами аритмии | |
| KR20130074808A (ko) | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 | |
| WO2012002921A1 (en) | Multiple dosage forms comprising fenofibrate or fenofibric acid in combination with hmg co a reductase inhibitors such as statins |